Immune signatures of chronic inflammatory human diseases driving cancer

The laboratory of Mathias Heikenwälder aims at understanding the different immune signatures of chronic inflammatory human diseases driving cancer - with the final aim to generate appropriate mouse models used for pre-clinical research and translation into the clinic. A focus of the laboratory is to understand how inflammation (induced by life-style factors or pathogens (e.g. viruses or bacteria)) drives cancer in regenerative organs (such as the liver or the gastrointestinal tract).

A particular research focus of the Mathias Heikenwälder laboratory is the elucidation of the molecular and cellular mechanisms causing fatty liver disease, subsequent inflammation,  tissue damage (called non-alcoholic steatohepatitis (NASH)) and resulting liver cancer. Life-style related factors have contributed to the fact that today liver cancer is the 4th most common cause for cancer-related death and the fastest rising cancer in the world.

Mainly caused by a sedentary life style and hypercaloric nutrition, NASH is one of the leading causes of chronic liver disease with the potential of evolving towards end-stage liver disease and hepatocellular carcinoma (HCC), even in the absence of cirrhosis. Every third American and European citizen has a fatty liver. Apart from becoming an increasingly prevalent indication for liver transplantation in cirrhotic and HCC patients, its burden on the healthcare system is also exerted by the increased number of non-cirrhotic NASH patients. Currently, there are no efficient therapies available that would either prevent NASH, revert fibrosis or block NASH to HCC transition.

The Heikenwälder laboratory focuses on comparative studies of human and animal model tissues, recapitulating human disease on a histo-pathological and pathophysiological level, engaging in classical molecular biology techniques complemented with sophisticated ways to receive as much information from tissue samples through histology (e.g. light microscopy/ immune fluorescence/ FISH/ in situ hybridization), other in vivo imaging techniques (e.g. MRI) as well as through FACS analyses for tissue homogenates. At the same time the systemic functional effects of pathologies and the interplay between several affected non-lymphoid organs and the immune system is investigated. Testing several therapeutic compounds in a single but also combinatorial fashion is executed in the Heikenwälder laboratory employing established and stratified pre-clinical mouse models.

In the past the Heikenwälder laboratory has elucidated how the adaptive and innate immune system drives NASH and affects therapy response (e.g. in the context of systemic liver cancer therapy) - which has led to the generation of drugs that are currently tested for clinical use. Mathias Heikenwälder is an elected member of the Leopoldina, most highly cited researcher world-wide from 2018-2022 (“Cross Topic” Web of Science) and has received several prestigious grants (ERC-Stg, ERC-CoG; ERC-POC) and awards (Prof. Max Cloetta award, Götz prize, Walther and Christine Richtzenhain award, Prof. Hans Peter Hofschneider award). In 2022 he has received the German Cancer award.  

Prof. Mathias Heikenwälder is a trained molecular biologist, with expertise in immunology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich). Since October 2015 he is Department head at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer. Since October 2022 he is director of the M3 Research Center, University Tübingen. Prof. Heikenwälder publishes his work in high-ranking journals and has established himself as an international leader in the field of liver cancer. Mathias Heikenwälder is the third most frequently cited German-speaking researcher in the field of cell biology in the last years and was one of the Highly Cited Researchers (Cross Fields) (Web of Science Group) in 2019, 2020, 2021 and 2022. Not only have his publications been widely cited by the research community, but they have also shifted fatty liver and liver cancer research in new directions - relevant to the day-to-day management of patients with fatty liver or liver cancer.

Interview
Video Startfolie
Immune signatures of chronic inflammatory human diseases driving cancer - Interview with Prof. Dr. Mathias Heikenwälder

Prof. Mathias Heikenwälder speaks about the research focus, the technologies executed as well as the overall translational work and overall goals of this research laboratory.

Beim Abspielen des Videos werden Daten an YouTube übertragen. Weitere Hinweise finden Sie in unserer Datenschutzerklärung.

  • Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

  • Cluster of Excellence “Image-guided and functionally instructed tumor therapies" (iFIT), University of Tübingen, Germany

  • Cluster of Excellence "Controlling Microbes to Fight Infections" (CMFI), University of Tübingen, Germany

The research focus of our laboratory is to investigate the role of chronic inflammation induced tissue damage and cancer caused by different environmental triggers:

  • Chronic infections with viruses, bacteria and their role in affecting the tumor directly (intratumoral) or the tumor microenvironment
  • Unhealthy life style (hyper caloric diet in combination with a sedentary life style; chronic smoking or alcohol abuse) and interconnected aberrant metabolism or chronic inflammation 
  • Generation of therapeutic concepts (e.g. combinatorial therapies; identification of novel targets) and life-style interventions (e.g. intermittent fasting)

 

NASH
non-alcoholic steatohepatitis
inflammation
driving cancer in regenerative organs
HCC
hepatocellular carcinoma

Selected publications

  • 2026

    Cholangiocarcinoma 2026: status quo, unmet needs and priorities

    Banales JM, Rodrigues PM, Affò S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Klümpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C; International CCA Consensus Consortium. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

    Nat Rev Gastroenterol Hepatol. 2026 Jan;23(1):65-96. doi: 10.1038/s41575-025-01153-w. Epub 2025 Dec 10. PMID: 41372578.

    https://doi.org/10.1038/s41575-025-01153-w
  • 2025

    Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation

    Kommoss KS, Krishnarajah S, Bieler T, Friebel E, Rindlisbacher L, Ramadori P, Häne P, Kam S, Müller F, Prokosch S, Rothermel U, Wu Y, Barletta F, Czemmel S, Nahnsen S, Helm D, Schneider M, Schäkel K, Enk A, Becher B, Heikenwälder M. Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation.

    Nat Commun. 2025 Dec 5;16(1):10881. doi: 10.1038/s41467-025-65894-7. PMID: 41350257; PMCID: PMC12680767.

    https://doi.org/10.1038/s41467-025-65894-7
  • 2025

    Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice

    Höckendorf U, Dutta S, Kloos A, Runtsch M, Zötsch C, Vosberg S, Wang Y, Kienreich S, Flasch B, Malovan G, Jäger V, Stanzer S, Prein S, Odinius TO, Wagner CV, Buschhorn L, Dill V, Perfler B, Haferlach T, Döhner K, Götze KS, Ruland J, Bassermann F, Wahida A, Heikenwälder M, Branca C, Schmöllerl J, Zuber J, Burk AC, Zeiser R, Sill H, Jayavelu AK, Zebisch A, Heuser M, Dengler MA, Jost PJ. Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice.

    Sci Transl Med. 2025 Nov 26;17(826):eadu3313. doi: 10.1126/scitranslmed.adu3313. Epub 2025 Nov 26. PMID: 41296826.

    https://doi.org/10.1126/scitranslmed.adu3313
  • 2025

    A global survey of taxa-metabolic associations across mouse microbiome communities

    Yilmaz B, Baertschi I, Meier KHU, Le Gac C, Jordi SBU, Black C, Li J, Lindholm AK; International Mouse Microbiota Investigators; König B, Sauer U, Stelling J, Macpherson AJ. A global survey of taxa-metabolic associations across mouse microbiome communities.

    Cell Host Microbe. 2025 Nov 12;33(11):1960-1976.e10. doi: 10.1016/j.chom.2025.10.010. Epub 2025 Nov 3. PMID: 41187758.

    https://doi.org/10.1016/j.chom.2025.10.010
  • 2025

    Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

    Scheiner B, Lombardi P, D'Alessio A, Kim G, Tafavvoghi M, Petrenko O, Goldin RD, Fulgenzi CAM, Torkpour A, Balcar L, Mauri FA, Pomej K, Himmelsbach V, Barsch M, Celsa C, Cabibbo G, Cheon J, Krall A, Hucke F, Di Tommaso L, Bernasconi M, Rimassa L, Samson A, Stefanini B, Mozayani B, Trauner M, Lackner C, Stauber R, Vasuri F, Piscaglia F, Bengsch B, Finkelmeier F, Peck-Radosavljevic M, Rasmussen Busund LT, Marafioti T, Rahbari M, Heikenwalder M, Pinter M, Chon HJ, Rakaee M, Pinato DJ. Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

    J Immunother Cancer. 2025 Oct 5;13(10):e010975. doi: 10.1136/jitc-2024-010975. PMID: 41052886; PMCID: PMC12506175.

    https://doi.org/10.1136/jitc-2024-010975
  • 2025

    Shooting for the stars: caspase-8-meteorin in MASH and fibrosis

    Gallage S, Bieler T, Heikenwalder M. Shooting for the stars: caspase-8-meteorin in MASH and fibrosis.

    Nat Metab. 2025 Oct;7(10):1965-1967. doi: 10.1038/s42255-025-01361-3. PMID: 41006903.

    https://doi.org/10.1038/s42255-025-01361-3
  • 2025

    Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models

    Crouchet E, Schaeffer E, Oudot MA, Moehlin J, Gadenne C, Jühling F, El Saghire H, Fujiwara N, Zhu S, Akter Rasha F, Durand SC, Charlot A, Ponsolles C, Martin R, Brignon N, Del Zompo F, Meiss-Heydmann L, Parnot M, Hamdane N, Heide D, Hetzer J, Heikenwälder M, Felli E, Pessaux P, Pochet N, Zoll J, Cunniff B, Hoshida Y, Mailly L, Baumert TF, Schuster C. Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models.

    J Clin Invest. 2025 Sep 11;135(21):e169395. doi: 10.1172/JCI169395. PMID: 40932790; PMCID: PMC12578407.

    https://doi.org/10.1172/jci169395
  • 2025

    Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity

    Silva de Oliveira R, Shupe A, Krause T, Richardo T, Ohland C, Sabachvili M, Bucher K, Hetzer J, Hörner S, Dauch D, Heikenwälder M, Trautwein C, Weber ANR, Klepsch V, McCoy KD, Mager LF. Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity.

    Cell Rep. 2025 Sep 23;44(9):116223. doi: 10.1016/j.celrep.2025.116223. Epub 2025 Sep 1. PMID: 40892540.

    https://doi.org/10.1016/j.celrep.2025.116223
  • 2025

    ATF6 activation alters colonic lipid metabolism causing tumour-associated microbial adaptation

    Coleman OI, Sorbie A, Riva A, von Stern M, Kuhls S, Selegato DM, Siegert L, Keidel I, Köhler N, Wirbel J, Kacprowski T, Dunkel A, Pauling JK, Plagge J, Mediel-Cuadra D, Wagner SJ, Chadly I, Bierwith S, Peng T, Metzler T, Li X, Heikenwälder M, Schafmayer C, Hinz S, Röder C, Röcken C, Zimmermann M, Rosenstiel P, Steiger K, Jesinghaus M, Liebisch G, Ecker J, Schmidt C, Zeller G, Janssen KP, Haller D. ATF6 activation alters colonic lipid metabolism causing tumour-associated microbial adaptation.

    Nat Metab. 2025 Sep;7(9):1830-1850. doi: 10.1038/s42255-025-01350-6. Epub 2025 Sep 1. PMID: 40890536; PMCID: PMC12460170.

    https://doi.org/10.1038/s42255-025-01350-6
  • 2025

    Mutual reinforcement of lymphotoxin-driven myositis and impaired autophagy in murine muscle

    Bremer J, Nagel J, Zschüntzsch J, Zajt KK, Palaz T, Blank T, Ikis A, Fischer LA, Sensmeyer ASM, Wiechers L, Reichelt JJ, Hofmann KP, Wolf MJ, Leuchtenberger C, Tripathi P, Einer C, Zischka H, Rothermel U, Eck AL, Reimann RR, Kana V, Rushing E, Aguzzi A, Prinz M, Liebetanz D, Odoardi F, Kuo CC, Weis J, Kraft F, Schmidt J, Heikenwälder M. Mutual reinforcement of lymphotoxin-driven myositis and impaired autophagy in murine muscle.

    Brain. 2025 Dec 4;148(12):4461-4481. doi: 10.1093/brain/awaf260. PMID: 40853947; PMCID: PMC12678053.

    https://doi.org/10.1093/brain/awaf260
  • 2025

    Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis

    Del Zompo F, Crouchet E, Ostyn T, Nehme Z, Messé M, Jühling F, Désert R, Vieira AT, Moehlin J, Nakib D, Andrews T, Perciani C, Chung S, Bader GD, McGilvray I, Caime C, Scaravaglio M, Carbone M, Invernizzi P, Yaqub S, Folseraas T, Karlsen TH, Shankar G, Primeaux M, Dhawan P, Banales JM, Roehlen N, Iacone R, Teixeira G, Heikenwälder M, Mailly L, MacParland S, Roskams T, Govaere O, Schuster C, Baumert TF. Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.

    J Hepatol. 2025 Dec;83(6):1305-1319. doi: 10.1016/j.jhep.2025.08.005. Epub 2025 Aug 20. PMID: 40846184.

    https://doi.org/10.1016/j.jhep.2025.08.005
  • 2025

    Ultra-high-scale cytometry-based cellular interaction mapping

    Vonficht D, Jopp-Saile L, Yousefian S, Flore V, Simó Vesperinas I, Teuber R, Avanesyan B, Luo Y, Röthemeier C, Grünschläger F, Fernandez-Vaquero M, Fregona V, Ordoñez-Rueda D, Schmalbrock LK, Deininger L, Yamachui Sitcheu AJ, Gu Z, Funk MC, Mikut R, Heikenwälder M, Eggert A, von Stackelberg A, Kobold S, Krönke J, Keller U, Trumpp A, Hegazy AN, Eckert C, Hübschmann D, Haas S. Ultra-high-scale cytometry-based cellular interaction mapping.

    Nat Methods. 2025 Sep;22(9):1887-1899. doi: 10.1038/s41592-025-02744-w. Epub 2025 Aug 7. PMID: 40775086; PMCID: PMC12446065.

    https://doi.org/10.1038/s41592-025-02744-w
  • 2025

    Expression of Bovine Meat and Milk Factor in Hepatocellular Carcinoma and Colorectal Liver Metastasis Patients

    Siqin S, Rahbari M, Ernst C, Grewe I, Gunst K, Neßling M, Kaden S, Richter K, Häfele L, Feuerbach L, Krunic D, Tessmer C, Hofmann I, Birgin E, Brobeil A, Rahbari N, Heikenwälder M, Bund T. Expression of Bovine Meat and Milk Factor in Hepatocellular Carcinoma and Colorectal Liver Metastasis Patients.

    J Med Virol. 2025 Aug;97(8):e70507. doi: 10.1002/jmv.70507. PMID: 40741925.

    https://doi.org/10.1002/jmv.70507
  • 2025

    Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma

    Prawira A, Xu H, Mei Y, Leow WQ, Nasir NJM, Reolo MJ, Otsuka M, Rahbari M, Chen Z, Weerasooriya M, Abdullah LB, Wu J, Hazirah SN, Wasser M, Chung A, Goh BK, Chow PK, Albani S, Lee J, Lim TKH, Zhai W, Dan YY, Goh GB, Heikenwälder MF, Zhang Y, Dasgupta R, Tai WMD, Liu H, Chen J, Chew V. Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma.

    Gut. 2025 Dec 5;75(1):105-118. doi: 10.1136/gutjnl-2025-335084. PMID: 40695620; PMCID: PMC12703262.

    https://doi.org/10.1136/gutjnl-2025-335084
  • 2025

    Non-antibiotics disrupt colonization resistance against enteropathogens

    Grießhammer A, de la Cuesta-Zuluaga J, Müller P, Gekeler C, Homolak J, Chang H, Schmitt K, Planker C, Schmidtchen V, Gallage S, Bohn E, Nguyen TH, Hetzer J, Heikenwälder M, Huang KC, Zahir T, Maier L. Non-antibiotics disrupt colonization resistance against enteropathogens.

    Nature. 2025 Aug;644(8076):497-505. doi: 10.1038/s41586-025-09217-2. Epub 2025 Jul 16. PMID: 40670795; PMCID: PMC12350171.

    https://doi.org/10.1038/s41586-025-09217-2
  • 2025

    Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

    Desert R, Gianonne F, Saviano A, Hoshida Y, Heikenwälder M, Nahon P, Baumert TF. Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.

    Gut Liver. 2025 Apr 3;2(1):s44355-025-00018-y. doi: 10.1038/s44355-025-00018-y. PMID: 40626281; PMCID: PMC7617876.

    https://doi.org/10.1038/s44355-025-00018-y
  • 2025

    Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD

    Deschler S, Pohl-Topcu J, Ramsauer L, Meiser P, Erlacher S, Schenk RP, Maurer HC, Shen P, Kager J, Zink J, Pistrenko K, Monte ER, Weber J, Wasmaier L, Laschinger M, Hüser N, Geisler F, Thorburn D, Nieß H, Wiedemann GM, Zischka H, Heikenwälder M, Kleigrewe K, Mogler C, Böttcher JP, Knolle PA, Schmid RM, Böttcher K. Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.

    J Hepatol. 2025 Dec;83(6):1364-1378. doi: 10.1016/j.jhep.2025.06.006. Epub 2025 Jun 19. PMID: 40543602.

    https://doi.org/10.1016/j.jhep.2025.06.006
  • 2025

    Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance

    Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.

    Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1. PMID: 40473819; PMCID: PMC12141660.

    https://doi.org/10.1038/s41598-025-04917-1
  • 2025

    Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

    Castoldi M, Roy S, Angendohr C, Pellegrino R, Vucur M, Singer MT, Buettner V, Dille MA, Wolf SD, Heij LR, Ghallab A, Albrecht W, Hengstler JG, Flügen G, Knoefel WT, Bode JG, Zender L, Neumann UP, Heikenwälder M, Longerich T, Roderburg C, Luedde T. Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.

    J Hepatol. 2025 Mar;82(3):499-511. doi: 10.1016/j.jhep.2024.08.025. Epub 2024 Sep 1. PMID: 40235270.

    https://doi.org/10.1016/j.jhep.2024.08.025
  • 2025

    Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis

    Outla Z, Oyman-Eyrilmez G, Korelova K, Prechova M, Frick L, Sarnova L, Bisht P, Novotna P, Kosla J, Bortel P, Borutzki Y, Bileck A, Gerner C, Rahbari M, Rahbari N, Birgin E, Kvasnicova B, Galisova A, Sulkova K, Bauer A, Jobe N, Tolde O, Sticova E, Rösel D, O'Connor T, Otahal M, Jirak D, Heikenwälder M, Wiche G, Meier-Menches SM, Gregor M. Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis.

    Elife. 2025 Mar 7;13:RP102205. doi: 10.7554/eLife.102205. PMID: 40052672; PMCID: PMC11893104.

    https://doi.org/10.7554/elife.102205
  • 2025

    A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development

    Schneider AT, Koppe C, Crouchet E, Papargyriou A, Singer MT, Büttner V, Keysberg L, Szydlowska M, Jühling F, Moehlin J, Chen MC, Leone V, Mueller S, Neuß T, Castoldi M, Lesina M, Bergmann F, Hackert T, Steiger K, Knoefel WT, Zaufel A, Kather JN, Esposito I, Gaida MM, Ghallab A, Hengstler JG, Einwächter H, Unger K, Algül H, Gassler N, Schmid RM, Rad R, Baumert TF, Reichert M, Heikenwalder M, Kondylis V, Vucur M, Luedde T. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development.

    Nat Commun. 2025 Feb 19;16(1):1765. doi: 10.1038/s41467-025-56493-7. PMID: 39971907; PMCID: PMC11839950.

    https://doi.org/10.1038/s41467-025-56493-7
  • 2025

    Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis

    Lim B, Kamal A, Gomez Ramos B, Adrian Segarra JM, Ibarra IL, Dignas L, Kindinger T, Volz K, Rahbari M, Rahbari N, Poisel E, Kafetzopoulou K, Böse L, Breinig M, Heide D, Gallage S, Barragan Avila JE, Wiethoff H, Berest I, Schnabellehner S, Schneider M, Becker J, Helm D, Grimm D, Mäkinen T, Tschaharganeh DF, Heikenwalder M, Zaugg JB, Mall M. Active repression of cell fate plasticity by PROX1 safeguards hepatocyte identity and prevents liver tumorigenesis.

    Nat Genet. 2025 Mar;57(3):668-679. doi: 10.1038/s41588-025-02081-w. Epub 2025 Feb 13. PMID: 39948437; PMCID: PMC11906372.

    https://doi.org/10.1038/s41588-025-02081-w
  • 2025

    Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity

    Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity.

    Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004. PMID: 39933899.

    https://doi.org/10.1016/j.ccell.2025.01.004
  • 2025

    RAGE is a key regulator of ductular reaction-mediated fibrosis during cholestasis

    Lam WM, Gabernet G, Poth T, Sator-Schmitt M, Oquendo MB, Kast B, Lohr S, de Ponti A, Weiß L, Schneider M, Helm D, Müller-Decker K, Schirmacher P, Heikenwälder M, Klingmüller U, Schneller D, Geisler F, Nahnsen S, Angel P. RAGE is a key regulator of ductular reaction-mediated fibrosis during cholestasis.

    EMBO Rep. 2025 Feb;26(3):880-907. doi: 10.1038/s44319-024-00356-7. Epub 2025 Jan 2. PMID: 39747668; PMCID: PMC11811172.

    https://doi.org/10.1038/s44319-024-00356-7
  • 2025

    Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

    Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeitlhoefler M, Mesropian A, Huguet-Pradell J, Haber PK, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D'Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt JU, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatic S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, Llovet JM. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

    J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19. PMID: 39709141; PMCID: PMC12086051.

    https://doi.org/10.1016/j.jhep.2024.12.016
  • 2025

    Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis

    Liner AG, van Gogh M, Roblek M, Heikenwalder M, Borsig L. Non-redundant roles of the CCR1 and CCR2 chemokine axes in monocyte recruitment during lung metastasis.

    Neoplasia. 2025 Jan;59:101089. doi: 10.1016/j.neo.2024.101089. Epub 2024 Nov 19. PMID: 39566333; PMCID: PMC11617888.

    https://doi.org/10.1016/j.neo.2024.101089
  • 2024

    Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma

    Büdeyri I, Guckelberger O, Oppermann E, Roy D, Sliwinski S, Becker F, Struecker B, Vogl TJ, Pascher A, Bechstein WO, Lorentzen A, Heikenwalder M, Juratli MA. Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma.

    Cells. 2024 Dec 25;14(1):6. doi: 10.3390/cells14010006. PMID: 39791707; PMCID: PMC11720075.

    https://doi.org/10.3390/cells14010006
  • 2024

    Opposing regulation of the STING pathway in hepatic stellate cells by NBR1 and p62 determines the progression of hepatocellular carcinoma

    Nishimura S, Linares JF, L'Hermitte A, Duran A, Cid-Diaz T, Martinez-Ordoñez A, Ruiz-Martinez M, Kudo Y, Marzio A, Heikenwalder M, Roberts LR, Diaz-Meco MT, Moscat J. Opposing regulation of the STING pathway in hepatic stellate cells by NBR1 and p62 determines the progression of hepatocellular carcinoma.

    Mol Cell. 2024 Dec 5;84(23):4660-4676.e10. doi: 10.1016/j.molcel.2024.09.026. Epub 2024 Oct 17. PMID: 39423823; PMCID: PMC12006816.

    https://doi.org/10.1016/j.molcel.2024.09.026
  • 2024

    Single-cell profiling of intrahepatic immune cells reveals an expansion of tissue-resident cytotoxic CD4+ T lymphocyte subset associated with pathogenesis of alcoholic-associated liver diseases

    Gao C, Wang S, Xie X, Ramadori P, Li X, Liu X, Ding X, Liang J, Xu B, Feng Y, Tan X, Wang H, Zhang Y, Zhang H, Zhang T, Mi P, Li S, Zhang C, Yuan D, Heikenwalder M, Zhang P. Single-cell Profiling of Intrahepatic Immune Cells Reveals an Expansion of Tissue-resident Cytotoxic CD4+ T Lymphocyte Subset Associated With Pathogenesis of Alcoholic-associated Liver Diseases.

    Cell Mol Gastroenterol Hepatol. 2025;19(2):101411. doi: 10.1016/j.jcmgh.2024.101411. Epub 2024 Sep 28. PMID: 39349248; PMCID: PMC11719870.

    https://doi.org/10.1016/j.jcmgh.2024.101411
  • 2024

    TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response

    Zheng M, Zhai Y, Yu Y, Shen J, Chu S, Focaccia E, Tian W, Wang S, Liu X, Yuan X, Wang Y, Li L, Feng B, Li Z, Guo X, Qiu J, Zhang C, Hou J, Sun Y, Yang X, Zuo X, Heikenwalder M, Li Y, Yuan D, Li S. TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response.

    Cell Metab. 2024 Sep 3;36(9):2086-2103.e9. doi: 10.1016/j.cmet.2024.06.008. Epub 2024 Jul 5. PMID: 38971153.

    https://doi.org/10.1016/j.cmet.2024.06.008
  • 2024

    HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

    Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier ML, Faure-Dupuy S, Riedl T, Lange S, Wisskirchen K, Thiele F, Cheng CC, Yuan D, Leone V, Schmidt R, Hünergard J, Geisler F, Unger K, Algül H, Schmid RM, Rad R, Wedemeyer H, Levrero M, Protzer U, Heikenwalder M. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx.

    JHEP Rep. 2024 Jun 6;6(10):101128. doi: 10.1016/j.jhepr.2024.101128. PMID: 39290403; PMCID: PMC11406364.

    https://doi.org/10.1016/j.jhepr.2024.101128
  • 2024

    Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome

    Gallage S, Irvine EE, Barragan Avila JE, Reen V, Pedroni SMA, Duran I, Ranvir V, Khadayate S, Pombo J, Brookes S, Heide D, Dharmalingham G, Choudhury AI, Singh I, Herranz N, Vernia S, Heikenwalder M, Gil J, Withers DJ. Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome. 


    Nat Aging. 2024 Nov;4(11):1544-1561. doi: 10.1038/s43587-024-00695-z. Epub 2024 Aug 29. PMID: 39210150; PMCID: PMC11564105.

    https://doi.org/10.1038/s43587-024-00695-z
  • 2024

    A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1

    Gallage S, Ali A, Barragan Avila JE, Seymen N, Ramadori P, Joerke V, Zizmare L, Aicher D, Gopalsamy IK, Fong W, Kosla J, Focaccia E, Li X, Yousuf S, Sijmonsma T, Rahbari M, Kommoss KS, Billeter A, Prokosch S, Rothermel U, Mueller F, Hetzer J, Heide D, Schinkel B, Machauer T, Pichler B, Malek NP, Longerich T, Roth S, Rose AJ, Schwenck J, Trautwein C, Karimi MM, Heikenwalder M. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.

    Cell Metab. 2024 Jun 4;36(6):1371-1393.e7. doi: 10.1016/j.cmet.2024.04.015. Epub 2024 May 7. PMID: 38718791.

    https://doi.org/10.1016/j.cmet.2024.04.015
  • 2023

    Intestinal B-cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

    Kotsiliti E, Leone V, Schuehle S, Govaere O, Li H, Wolf MJ, Horvatic H, Bierwirth S, Hundertmark J, Inverso D, Zizmare L, Sarusi-Portuguez A, Gupta R, O'Connor T, Giannou AD, Shiri AM, Schlesinger Y, Beccaria MG, Rennert C, Pfister D, Öllinger R, Gadjalova I, Ramadori P, Rahbari M, Rahbari N, Healy ME, Fernández-Vaquero M, Yahoo N, Janzen J, Singh I, Fan C, Liu X, Rau M, Feuchtenberger M, Schwaneck E, Wallace SJ, Cockell S, Wilson-Kanamori J, Ramachandran P, Kho C, Kendall TJ, Leblond AL, Keppler SJ, Bielecki P, Steiger K, Hofmann M, Rippe K, Zitzelsberger H, Weber A, Malek N, Luedde T, Vucur M, Augustin HG, Flavell R, Parnas O, Rad R, Pabst O, Henderson NC, Huber S, Macpherson A, Knolle P, Claassen M, Geier A, Trautwein C, Unger K, Elinav E, Waisman A, Abdullah Z, Haller D, Tacke F, Anstee QM, Heikenwalder M. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.

    J Hepatol. 2023 Aug;79(2):296-313. doi: 10.1016/j.jhep.2023.04.037. Epub 2023 May 22. PMID: 37224925; PMCID: PMC10360918.

    https://doi.org/10.1016/j.jhep.2023.04.037
  • 2021

    XCR1+ type 1 conventional dendritic cells drive liver pathology in Non-Alcoholic Steatohepatitis

    Deczkowska A, David E, Ramadori P, Pfister D, Safran M, Li B, Giladi A, Jaitin DA, Barboy O, Cohen M, Yofe I, Gur C, Shlomi-Loubaton S, Henri S, Suhail Y, Qiu M, Kam S, Hermon H, Lahat E, Ben Yakov G, Cohen-Ezra O, Davidov Y, Likhter M, Goitein D, Roth S, Weber A, Malissen B, Weiner A, Ben-Ari Z, Heikenwälder M, Elinav E, Amit I. XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.

    Nat Med. 2021 Jun;27(6):1043-1054. doi: 10.1038/s41591-021-01344-3. Epub 2021 May 20. Erratum in: Nat Med. 2022 Jan;28(1):214. doi: 10.1038/s41591-021-01668-0. PMID: 34017133.

    https://doi.org/10.1038/s41591-021-01344-3
  • 2021

    NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

    Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. PMID: 33762733; PMCID: PMC8046670.

    https://doi.org/10.1038/s41586-021-03362-0
  • 2020

    Inhibition of LTβR signalling activates WNT-induced regeneration in lung

    Conlon TM, John-Schuster G, Heide D, Pfister D, Lehmann M, Hu Y, Ertüz Z, Lopez MA, Ansari M, Strunz M, Mayr C, Angelidis I, Ciminieri C, Costa R, Kohlhepp MS, Guillot A, Günes G, Jeridi A, Funk MC, Beroshvili G, Prokosch S, Hetzer J, Verleden SE, Alsafadi H, Lindner M, Burgstaller G, Becker L, Irmler M, Dudek M, Janzen J, Goffin E, Gosens R, Knolle P, Pirotte B, Stoeger T, Beckers J, Wagner D, Singh I, Theis FJ, de Angelis MH, O'Connor T, Tacke F, Boutros M, Dejardin E, Eickelberg O, Schiller HB, Königshoff M, Heikenwalder M, Yildirim AÖ. Inhibition of LTβR signalling activates WNT-induced regeneration in lung.

    Nature. 2020 Dec;588(7836):151-156. doi: 10.1038/s41586-020-2882-8. Epub 2020 Nov 4. Erratum in: Nature. 2021 Jan;589(7842):E6. doi: 10.1038/s41586-020-03087-6. PMID: 33149305; PMCID: PMC7718297.

    https://doi.org/10.1038/s41586-020-2882-8
  • 2019

    Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention

    O'Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken UE, Knolle PA, von Baumgarten L, Keller U, Heikenwalder M. Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.

    Cancer Cell. 2019 Sep 16;36(3):250-267.e9. doi: 10.1016/j.ccell.2019.08.001. Erratum in: Cancer Cell. 2025 Jul 14;43(7):1377-1384. doi: 10.1016/j.ccell.2025.06.009. PMID: 31526758.

    https://doi.org/10.1016/j.ccell.2019.08.001
  • 2019

    Platelet GPIba is a mediator and potential interventional target for NASH and subsequent liver cancer

    Malehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard BGJ, Rath D, Ali A, Wolf MJ, Drescher H, Healy ME, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson CL, Leslie J, O'Connor T, Weston CJ, Chauhan A, Adams DH, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers MN, Notohamiprodjo M, Geisler T, Withers DJ, Ware J, Mann DA, Augustin HG, Vegiopoulos A, Milsom MD, Rose AJ, Lalor PF, Llovet JM, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle PA, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

    Nat Med. 2019 Apr;25(4):641-655. doi: 10.1038/s41591-019-0379-5. Epub 2019 Apr 1. Erratum in: Nat Med. 2022 Mar;28(3):600. doi: 10.1038/s41591-022-01693-7. PMID: 30936549; PMCID: PMC12452109.

    https://doi.org/10.1038/s41591-019-0379-5
  • 2018

    Single cell polarity in liquid phase facilitates tumour metastasis

    Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M. Single cell polarity in liquid phase facilitates tumour metastasis.

    Nat Commun. 2018 Feb 28;9(1):887. doi: 10.1038/s41467-018-03139-6. PMID: 29491397; PMCID: PMC5830403.

    https://doi.org/10.1038/s41467-018-03139-6
  • 2017

    Kupffer-cell derived TNF triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS

    Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Öllinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Höchst B, Wohlleber D, Jörs S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Hüser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M. Kupffer Cell-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS.

    Cancer Cell. 2017 Jun 12;31(6):771-789.e6. doi: 10.1016/j.ccell.2017.05.006. Erratum in: Cancer Cell. 2026 Jan 31:S1535-6108(26)00052-8. doi: 10.1016/j.ccell.2026.01.013. PMID: 28609656; PMCID: PMC7909318.

    https://doi.org/10.1016/j.ccell.2017.05.006
  • 2017

    Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development

    Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kähne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrissa-Altés S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Hüser N, Davis RJ, Müllhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M, Weber A. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development.

    Cancer Cell. 2017 Sep 11;32(3):342-359.e10. doi: 10.1016/j.ccell.2017.08.010. PMID: 28898696; PMCID: PMC5598544.

    https://doi.org/10.1016/j.ccell.2017.08.010
  • 2015

    Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

    Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G, Schwartz ME, Kobayashi M, Kumada H, Berger M, Pappo O, Rajewsky K, Hoshida Y, Karin M, Heikenwalder M, Ben-Neriah Y, Pikarsky E. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma.

    Nat Immunol. 2015 Dec;16(12):1235-44. doi: 10.1038/ni.3290. Epub 2015 Oct 26. PMID: 26502405; PMCID: PMC4653079.

    https://doi.org/10.1038/ni.3290
  • 2014

    Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes

    Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschöp M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. 

    Cancer Cell. 2014 Oct 13;26(4):549-64. doi: 10.1016/j.ccell.2014.09.003. PMID: 25314080.

    https://doi.org/10.1016/j.ccell.2014.09.003
  • 2014

    Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

    Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

    Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20. PMID: 24557838; PMCID: PMC6309542.

    https://doi.org/10.1126/science.1243462
  • 2013

    Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection

    Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z, Schildberg FA, Odenthal M, Dienes HP, van Rooijen N, Schmitt E, Garbi N, Croft M, Kurts C, Kubes P, Protzer U, Heikenwalder M, Knolle PA. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection.

    Nat Immunol. 2013 Jun;14(6):574-83. doi: 10.1038/ni.2573. Epub 2013 Apr 14. PMID: 23584070.

    https://doi.org/10.1038/ni.2573
  • 2012

    Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway

    Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Stürzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway.

    Cancer Cell. 2012 Jul 10;22(1):91-105. doi: 10.1016/j.ccr.2012.05.023. Erratum in: Cancer Cell. 2025 May 12;43(5):988-992. doi: 10.1016/j.ccell.2025.04.012. PMID: 22789541.

    https://doi.org/10.1016/j.ccr.2012.05.023
  • 2012

    Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis

    Seleznik GM, Reding T, Romrig F, Saito Y, Mildner A, Segerer S, Sun LK, Regenass S, Lech M, Anders HJ, McHugh D, Kumagi T, Hiasa Y, Lackner C, Haybaeck J, Angst E, Perren A, Balmer ML, Slack E, MacPherson A, Manz MG, Weber A, Browning JL, Arkan MC, Rülicke T, Aguzzi A, Prinz M, Graf R, Heikenwalder M. Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis.

    Gastroenterology. 2012 Nov;143(5):1361-1374. doi: 10.1053/j.gastro.2012.07.112. Epub 2012 Aug 2. PMID: 22863765.

    https://doi.org/10.1053/j.gastro.2012.07.112
  • 2009

    A lymphotoxin-driven pathway to hepatocellular carcinoma

    Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M. A lymphotoxin-driven pathway to hepatocellular carcinoma.

    Cancer Cell. 2009 Oct 6;16(4):295-308. doi: 10.1016/j.ccr.2009.08.021. Erratum in: Cancer Cell. 2009 Nov 6;16(5):447. Erratum in: Cancer Cell. 2025 Oct 13;43(10):1968-1972. doi: 10.1016/j.ccell.2025.08.005. PMID: 19800575; PMCID: PMC4422166.

    https://doi.org/10.1016/j.ccr.2009.08.021

Reviews

  • 2023

    Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation

    Yahoo N, Dudek M, Knolle P, Heikenwälder M. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.

    J Hepatol. 2023 Aug;79(2):538-551. doi: 10.1016/j.jhep.2023.02.033. Epub 2023 Mar 7. PMID: 36893854.

    https://doi.org/10.1016/j.jhep.2023.02.033
  • 2022

    A researcher's guide to preclinical mouse NASH models

    Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, Ali A, Malek NP, Anstee QM, Heikenwalder M. A researcher's guide to preclinical mouse NASH models.

    Nat Metab. 2022 Dec;4(12):1632-1649. doi: 10.1038/s42255-022-00700-y. Epub 2022 Dec 20. PMID: 36539621.

    https://doi.org/10.1038/s42255-022-00700-y
  • 2021

    The immunological and metabolic landscape in primary and metastatic liver cancer

    Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer.

    Nat Rev Cancer. 2021 Sep;21(9):541-557. doi: 10.1038/s41568-021-00383-9. Epub 2021 Jul 29. PMID: 34326518.

    https://doi.org/10.1038/s41568-021-00383-9
  • 2019

    From NASH to HCC: current concepts and future challenges

    Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges.

    Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7. PMID: 31028350.

    https://doi.org/10.1038/s41575-019-0145-7
  • 2018

    The immunology of hepatocellular carcinoma

    Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma.

    Nat Immunol. 2018 Mar;19(3):222-232. doi: 10.1038/s41590-018-0044-z. Epub 2018 Jan 29. PMID: 29379119.

    https://doi.org/10.1038/s41590-018-0044-z
  • 2016

    Immune receptor for pathogenic α-synuclein

    Jucker M, Heikenwalder M. Immune receptor for pathogenic α-synuclein. 


    Science. 2016 Sep 30;353(6307):1498-1499. doi: 10.1126/science.aai9377. PMID: 27708090.


    https://doi.org/10.1126/science.aai9377